Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Actilyse
2. Activase
3. Alteplase
4. Lysatec Rt Pa
5. Lysatec Rt-pa
6. Lysatec Rtpa
7. Plasminogen Activator, Tissue
8. Plasminogen Activator, Tissue Type
9. Plasminogen Activator, Tissue-type
10. T Plasminogen Activator
11. T-plasminogen Activator
12. Tisokinase
13. Tissue Activator D 44
14. Tissue Activator D-44
15. Tissue Plasminogen Activator
16. Tissue Type Plasminogen Activator
17. Tissue-type Plasminogen Activator
18. Ttpa
1. 177799-16-5
2. Ttpa
3. 9,10-bis[n,n-di(p-tolyl)amino]anthracene
4. 9-n,9-n,10-n,10-n-tetrakis(4-methylphenyl)anthracene-9,10-diamine
5. N9,n9,n10,n10-tetra-p-tolylanthracene-9,10-diamine
6. Schembl1261345
7. Dtxsid30629288
8. Cha79916
9. 9,10-anthracenediamine, N9,n9,n10,n10-tetrakis(4-methylphenyl)-
10. Mfcd12022465
11. Akos027252460
12. As-71559
13. 9,10-bis[n,n-di(p-tolyl)amino]anthracene, 98%
14. N,n,n',n'-tetrakis(p-tolyl)anthracene-9,10-diamine
15. N,n,n',n'-tetrakis(4-methylphenyl)-9,10-anthracenediamine
16. N~9~,n~9~,n~10~,n~10~-tetrakis(4-methylphenyl)anthracene-9,10-diamine
17. N9,n9,n10,n10-tetrakis(4-methylphenyl)anthracene-9,10-diamine
| Molecular Weight | 568.7 g/mol |
|---|---|
| Molecular Formula | C42H36N2 |
| XLogP3 | 12.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 6 |
| Exact Mass | 568.287849157 g/mol |
| Monoisotopic Mass | 568.287849157 g/mol |
| Topological Polar Surface Area | 6.5 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 728 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
NDC Package Code : 12714-082
Start Marketing Date : 1987-11-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50mg/50mg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 12714-083
Start Marketing Date : 1987-11-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100mg/100mg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 68594-090
Start Marketing Date : 2024-05-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (2.5mg/2.5mg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 63552-041
Start Marketing Date : 2001-09-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (2.2mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength : 2mg
Packaging :
Approval Date : 16/12/2010
Application Number : 20100526000080
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength :
Packaging :
Approval Date : 04/05/1990
Application Number : 19900504000200
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : ACTIVASE
Dosage Form : VIAL; SINGLE-USE
Dosage Strength : 100MG/VIAL
Packaging :
Approval Date :
Application Number : 103172
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : ACTIVASE
Dosage Form : VIAL; SINGLE-USE
Dosage Strength : 50MG/VIAL
Packaging :
Approval Date :
Application Number : 103172
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : CATHFLO ACTIVASE
Dosage Form : VIAL
Dosage Strength : 2MG/VIAL
Packaging :
Approval Date :
Application Number : 103172
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength :
Packaging :
Approval Date : 09/01/2014
Application Number : 20130904000050
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength : 2mg
Packaging :
Approval Date : 26/11/2014
Application Number : 20140403000048
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength :
Packaging :
Approval Date : 09/01/2014
Application Number : 20130904000043
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength :
Packaging :
Approval Date : 26/11/2014
Application Number : 20140403000062
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Actilyse
Dosage Form : Injection/Infusion Solution
Dosage Strength :
Packaging :
Approval Date : 10/11/2011
Application Number : 20110409000014
Regulatory Info : Deregistered
Registration Country : Sweden

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 1,372
2018 Revenue in Millions : 1,323
Growth (%) : 4

Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,472
2019 Revenue in Millions : 1,484
Growth (%) : -1

Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 1,412
2020 Revenue in Millions : 1,400
Growth (%) : -1

Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,287
2021 Revenue in Millions : 1,412
Growth (%) : -9

Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,361
2022 Revenue in Millions : 1,287
Growth (%) : 0

Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 713
2023 Revenue in Millions : 617
Growth (%) : 16

Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 1,324
2023 Revenue in Millions : 1,361
Growth (%) : -3

Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 10
2017 Revenue in Millions : 0
Growth (%) : New Launch

Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 1,097
2015 Revenue in Millions : 926
Growth (%) : 19

Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 1,292
2016 Revenue in Millions : 1,174
Growth (%) : 10

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
16 Jun 2023
Reply
01 Jul 2022
Reply
07 Apr 2021
Reply
10 May 2019
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
65
PharmaCompass offers a list of Alteplase API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Alteplase manufacturer or Alteplase supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Alteplase manufacturer or Alteplase supplier.
PharmaCompass also assists you with knowing the Alteplase API Price utilized in the formulation of products. Alteplase API Price is not always fixed or binding as the Alteplase Price is obtained through a variety of data sources. The Alteplase Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Alteplase manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alteplase, including repackagers and relabelers. The FDA regulates Alteplase manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alteplase API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Alteplase supplier is an individual or a company that provides Alteplase active pharmaceutical ingredient (API) or Alteplase finished formulations upon request. The Alteplase suppliers may include Alteplase API manufacturers, exporters, distributors and traders.
click here to find a list of Alteplase suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Alteplase as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Alteplase API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Alteplase as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Alteplase and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Alteplase NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Alteplase suppliers with NDC on PharmaCompass.
Alteplase Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alteplase GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alteplase GMP manufacturer or Alteplase GMP API supplier for your needs.
A Alteplase CoA (Certificate of Analysis) is a formal document that attests to Alteplase's compliance with Alteplase specifications and serves as a tool for batch-level quality control.
Alteplase CoA mostly includes findings from lab analyses of a specific batch. For each Alteplase CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alteplase may be tested according to a variety of international standards, such as European Pharmacopoeia (Alteplase EP), Alteplase JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alteplase USP).